Home > News > Headline News > Archive

Click on title to read the full article.

MiR-181 molecule tied to breast cancer metastasis

December 18, 2012

By Case Western Reserve University School of Medicine, News Medical

Researchers at Case Western Reserve University School of Medicine have identified a molecule linked to more aggressive forms of breast cancer - a discovery that could point the way to potential cures.

 

Novel, Targetable Mechanism of Resistance Identified in Breast Cancer

December 14, 2012

By Anna Azvolinsky, PhD

Scientists have identified a novel way metastatic breast cancer cells can bypass targeted therapy. Breast cancer cells with an active phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway treated with a PI3K inhibitor are able to turn up a different pathway, the Janus family of kinases and associated signal transducers and activators of transcription (JAK2/STAT5) pathway, and continue to grow. The results, published in Cancer Cell have broad implications because the PI3K pathway is important in a variety of different cancers.

 

Bevacizumab Fails as Add-On in Breast Cancer

December 6, 2012

By Ed Susman, MedPage Today

Adding the targeted anti-vascular endothelial growth factor drug bevacizumab (Avastin) to endocrine therapy did not extend time to disease progression among women with advanced breast cancer, researchers reported here.

 

What Greater Gift Than Recognition?

December 3, 2012

By Nancy Davis, Huffington Post's The Blog

I believe we can herald 2012 as one of the greatest exposures for stage IV breast cancer of this century. I wasn't suffocated by the "pink haze" this year. Even Komen finally came out with a stage IV ad... a monumental feat for us! I thank Nancy Brinker for opening her eyes, even though it took so long to get us recognition.